FDA approved afinitor for the treatment of noncancerous renal tumors caused by rare genetic diseases
-
Last Update: 2012-04-27
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: China Council for the promotion of medicine 2012-04-27 US Food and Drug Administration today approved the use of afinitor (everolimus) in the treatment of non cancer renal tumor (renal angiomyolipoma) complex tuberous sclerosis (TSC) patients without immediate surgery, which is the first drug approved specifically for this disease TSC is a rare genetic disease, which can cause the growth of various non cancer tumors in brain, kidney and other important organs It affects as many as 40000 people in the United States, with an estimated 70 to 80 percent of them suffering from kidney disease TSC usually causes a variety of tumors in both kidneys As the tumor volume increases, it compresses normal renal tissue, leading to renal failure and hemorrhage Daily administration of afinitor one tablet at a time can prevent the activity of some uncontrolled protein mTOR kinase, which plays a key role in the growth of various non cancer tumors in TSC patients Original link: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm32048.htm
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
